Media Summary: A roundtable discussion, moderated by Sagar Lonial, MD, FACP, Blood Cancers Today Editor-in-Chief, of the Winship In this discussion, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College ... Surbhi Sidana, MD, Stanford University, Stanford, CA, shares her perspectives on how

Treatment Sequencing Considerations For Using Car T In Patients With Multiple Myeloma - Detailed Analysis & Overview

A roundtable discussion, moderated by Sagar Lonial, MD, FACP, Blood Cancers Today Editor-in-Chief, of the Winship In this discussion, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College ... Surbhi Sidana, MD, Stanford University, Stanford, CA, shares her perspectives on how In this discussion, Sham Mailankody, MBBS, Memorial Sloan Kettering Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Amrita Krishnan, MD, City of Hope, Duarte, CA, discusses the

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, expresses optimism regarding current immunotherapeutic ... At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, ... Borja Puertas-Martinez, MD, University Hospital of Salamanca, Salamanca, Spain, discusses a study that aimed During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and

Photo Gallery

Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma
Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more
How to best sequence bispecific antibodies and CAR-T therapy in multiple myeloma
Treatment considerations with GPRC5D-targeted therapies in myeloma: optimizing sequencing
Challenges with the real-world use of CAR-T therapy in multiple myeloma
Considering the sequencing of CAR T-cell therapy and bispecific antibodies in multiple myeloma
Overcoming challenges in CAR T-cell therapy for multiple myeloma
CAR-T, Bispecifics  or ADCs First? Sequencing Myeloma BCMA-Directed Therapies Explained!
Treating Multiple Myeloma with Immunotherapy/CAR T-cell Therapy | Mass General Brigham
Remission of multiple myeloma with CAR T-cell therapy
Allogeneic CAR-T Therapy: Understanding This New Approach in Myeloma Immunotherapy
Optimizing CAR-T therapy for patients with multiple myeloma in the real-world
Sponsored
Sponsored
View Detailed Profile
Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma

Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma

A roundtable discussion, moderated by Sagar Lonial, MD, FACP, Blood Cancers Today Editor-in-Chief, of the Winship

Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more

Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more

In this discussion, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College ...

Sponsored
How to best sequence bispecific antibodies and CAR-T therapy in multiple myeloma

How to best sequence bispecific antibodies and CAR-T therapy in multiple myeloma

Surbhi Sidana, MD, Stanford University, Stanford, CA, shares her perspectives on how

Treatment considerations with GPRC5D-targeted therapies in myeloma: optimizing sequencing

Treatment considerations with GPRC5D-targeted therapies in myeloma: optimizing sequencing

In this discussion, Sham Mailankody, MBBS, Memorial Sloan Kettering

Challenges with the real-world use of CAR-T therapy in multiple myeloma

Challenges with the real-world use of CAR-T therapy in multiple myeloma

Thomas Martin, MD, UCSF Helen Diller Family Comprehensive

Sponsored
Considering the sequencing of CAR T-cell therapy and bispecific antibodies in multiple myeloma

Considering the sequencing of CAR T-cell therapy and bispecific antibodies in multiple myeloma

Amrita Krishnan, MD, City of Hope, Duarte, CA, discusses the

Overcoming challenges in CAR T-cell therapy for multiple myeloma

Overcoming challenges in CAR T-cell therapy for multiple myeloma

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, expresses optimism regarding current immunotherapeutic ...

CAR-T, Bispecifics  or ADCs First? Sequencing Myeloma BCMA-Directed Therapies Explained!

CAR-T, Bispecifics or ADCs First? Sequencing Myeloma BCMA-Directed Therapies Explained!

HTUmyeloma Wondering how to

Treating Multiple Myeloma with Immunotherapy/CAR T-cell Therapy | Mass General Brigham

Treating Multiple Myeloma with Immunotherapy/CAR T-cell Therapy | Mass General Brigham

What is immunotherapy and how is

Remission of multiple myeloma with CAR T-cell therapy

Remission of multiple myeloma with CAR T-cell therapy

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, ...

Allogeneic CAR-T Therapy: Understanding This New Approach in Myeloma Immunotherapy

Allogeneic CAR-T Therapy: Understanding This New Approach in Myeloma Immunotherapy

Allogeneic

Optimizing CAR-T therapy for patients with multiple myeloma in the real-world

Optimizing CAR-T therapy for patients with multiple myeloma in the real-world

In this video, Doris Hansen, MD, Moffitt

CAR T and Bispecific Antibody Therapies in Multiple Myeloma

CAR T and Bispecific Antibody Therapies in Multiple Myeloma

Shonali Midha, MD, discusses the

The importance of bridging therapy prior to CAR-T in patients with multiple myeloma

The importance of bridging therapy prior to CAR-T in patients with multiple myeloma

In this video, Doris Hansen, MD, Moffitt

How does CAR T cell therapy work?

How does CAR T cell therapy work?

CAR

Optimizing bridging therapy prior to CAR T-cell therapy in multiple myeloma

Optimizing bridging therapy prior to CAR T-cell therapy in multiple myeloma

Doris Hansen, MD, Moffitt

CAR-T vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing

CAR-T vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing

Borja Puertas-Martinez, MD, University Hospital of Salamanca, Salamanca, Spain, discusses a study that aimed

Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in R/R multiple myeloma

Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in R/R multiple myeloma

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and

Sean's Story: CAR T-Cell Therapy Treatment for Multiple Myeloma

Sean's Story: CAR T-Cell Therapy Treatment for Multiple Myeloma

CAR T

The use of CAR T-cells in multiple myeloma

The use of CAR T-cells in multiple myeloma

The utilization of